CanMart has entered into a distribution agreement with Australia-based Cannim to bring its award-winning medical cannabis products to UK patients.
Under the agreement, Cannim’s Lumir range of full-spectrum medical cannabis oils will be available to UK patients. The products will be available through UK-based CanMart – an approved pharmaceutical importer and distributor which supplies pharmacies and clinics in the country.
CEO and Director of Akanda, Tej Virk, commented: “Patients in the UK will now have access to Cannim’s high-quality Jamaica-grown medical cannabis products for the first time.
“This is another step in our effort to establish an international supply chain based on a unique ‘open marketplace’ model that provides patients with maximum choice.
“By bringing together the best third-party products from around the world and combining it with our own high-quality products cultivated at our Bophelo campus in Lesotho from DNA Genetics, we are democratising access to medical cannabis.”
Cannim’s chief commercial officer, Stuart Marsh, added: “The UK is an important link in a string of new market entries obtained by Cannim in recent months, including securing access to the burgeoning German medicinal cannabis market in August launching into Australia under the Hummingbud brand in September.
“Thanks to our partnership with CanMart, we are pleased to add the UK to that footprint. We have been impressed by CanMart’s deep expertise and knowledge of the UK market, which has been instrumental in securing the relevant approvals to introduce British patients to our products.”
Cannim’s Lumir CBD50 was recently recognised as CBD Product of the Year at the Australian Cannabis Industry Awards.
Akanda recently completed the acquisition of its parent company Halo Collective‘s subsidiaries Bophelo Bio Science & Wellness Ltd. and CanMart Ltd. which Virk commented marked a major step towards Akanda’s establishment as an international medical cannabis company.
[activecampaign form=31]
